Rocklatan vs. Latanoprost for Glaucoma and Ocular Hypertension
This study is comparing two eye drop treatments for open-angle glaucoma (OAG) or ocular hypertension (OHT). You would receive a combination drug called Netarsudil 0.02%/latanoprost 0.005% in one eye and Latanoprost 0.005% in your other eye. Doctors want to see how well each treatment lowers the pressure inside your eye (intraocular pressure or IOP) over 24 hours. To join, you need to be at least 18 years old and have a diagnosis of OHT or mild-to-moderate OAG in both eyes, with an IOP between 18 and 34 mmHg. The study's success will be measured by how much each treatment reduces your IOP after two weeks. The current recruitment status is unclear.
- Study design
- This is a double-masked study, meaning neither you nor your doctor will know which eye receives which treatment. It's a paired-contralateral study, comparing the two treatments in your two eyes. About 30 participants are planned.
- What's involved
- You would administer study medication as one drop in each eye, once daily at night, for 14 consecutive days. Your total participation, including any washout period from previous treatments, could be up to 10 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints measure changes in eye pressure after 2 weeks of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07325240
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Recruiting
PHASE4Ages 18+InterventionalTreatmentMayo ClinicInvestigator-initiated
~30 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutionLatanoprost 0.005% Ophthalmic Solution
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in mean Intraocular Pressure (IOP)
Measured over Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Arthur J Sit, MD, MS · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit.
Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit
Be able and willing to provide signed informed consent and follow study instructions
Ability to cooperate with the examinations required for the study and be able to attend all study visits
If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits.
Best-corrected visual acuity (BCVA) using ETDRS chart of +0.4 logMAR units (Snellen equivalent \~ 20/50) or better in each eye
Exclusion
Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye
Severe glaucomatous damage
Difference in IOP between eyes \> 4 mmHg (unmedicated) at any baseline time point
Use of more than two ocular hypotensive medications within 30 days of screening
Chronic or recurrent inflammatory eye diseases in either eye
Ocular infection or ocular inflammation in the past 3 months in either eye
Ocular trauma other than corneal abrasion within the past 6 months in either eye
Clinically significant retinal disease (e.g., severe diabetic retinopathy, exudative or severe non-exudative macular degeneration, macular edema, retinal vein or artery occlusion) in either eye
Cornea pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, keratoconus) in either eye
Myopia greater than -6.00D, or hyperopia greater than +2.00D in either eye
Central corneal thickness less than 480 μm or greater than 620 μm in either eye
Previous intraocular surgery other than routine uncomplicated cataract surgery in either eye
Previous glaucoma intraocular surgery or glaucoma laser procedures (except SLT performed more than 6 months ago) in either eye
Unilateral intraocular surgery or glaucoma laser procedures
Previous corneal refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking, etc.)
Severe dry eye in either eye
Use of ocular medications in either eye within 30 days of screening, with the exception of IOP-lowering medications (which must be washed out according to the provided schedule), and lubricating drops for dry eye (which may be used throughout the study)
Known hypersensitivity to any component of the formulation (eg, benzalkonium chloride, etc.), or to topical anesthetic
Clinically significant systemic diseases which might interfere with the study
Participation in any interventional study within 30 days prior to screening visit
Changes of systemic medication that could have an effect on IOP within 30 days prior to screening, or anticipated during the study including, β-adrenergic antagonists, α-adrenergic agonists and antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers
Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including: systemic/inhaled steroids, calcium channel blockers, diuretics, and vasodilators
Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative pregnancy test result at the screening examination and must not intend to become pregnant during the study
Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications
What this trial measures
- Change in mean Intraocular Pressure (IOP)Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline
Change in mean IOP from baseline at each time point for Latanoprost
- Change in mean IOPChange in mean IOP after 2 weeks of treatment with Rocklatan compared to baseline
Change in mean IOP from baseline at each time point for Rocklatan
- Change in mean IOPChange in mean IOP from baseline after 2 weeks of treatment with latanoprost minus change in mean IOP from baseline after 2 weeks of treatment with Rocklatan
Change in mean IOP from Latanoprost at each time point for Rocklatan